Genomics Immunology and Healthcare ETF (IDNA)

$22.05 0.22 (0.99%)

12:22 EDT IDNA Stock Quote Delayed 30 Minutes

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Volume:

Previous Close -

Market Cap 1.29M

PE Ratio -

EPS -

Volume (Avg. Vol.) 9,666

Day's Range $22.05 - $22.35

52-Week Range $17.33 - $25.52

Dividend & Yield $0.07 (0.32%)

IDNA Stock Predictions, Articles, and Genomics Immunology and Healthcare ETF News

From the Web

ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM

From Talk Markets Oct 21, 2021

The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage.

Take A Look At The Top-Performing Biotech ETFs YTD

From Talk Markets Oct 2, 2021

The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq Biotechnology Index rising about 6.9% so far in 2021.

A Comprehensive Guide To Genomic ETFs

From Talk Markets Jul 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the space.

Moderna ETFs To Rise On Positive COVID-19 Vaccine Updates

From Talk Markets Jul 4, 2021

The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to Moderna.

Moderna ETFs to Shine on Vaccine News as Outbreak Worsens

From Talk Markets Nov 18, 2020

The first company to begin human clinical trials of its coronavirus vaccine candidate in the United States — Moderna — has once again come up with encouraging study data relating to mRNA-1273.

ETFs in Focus on Bayer's Bet on Gene Therapy

From Talk Markets Oct 30, 2020

Merger and acquisition activities have heated up in recent months and the niche spaces are in the limelight. After the telemedicine industry, gene therapy stocks jumped on the bandwagon.

ADVERTISEMENT